Bosslet et al. "Fusion Protein-Mediated Tumor Selective Prodrug Activation" from Contributions to Oncology, (Eds. Huber & Queisser), vol. 48: 160-169, 1995. |
Bosslet et al. Tumor Targeting, vol. 1: 45-50, 1995. |
Bosslet et al. Cell Biophys., vol. 24/25: 51-63, 1994. |
Haisma et al. Cell Biophys., vol. 24/25: 185-192, 1994. |
Bosslet, Klaus, et al., "Tumor-selective Prodrug Activation by Fusion Protein-mediated Catalysis," Cancer Research, 54 (1994), pp. 2151-2159. |
Gesson, J.P., et al., "Prodrugs of anthracyclines for chemotherapy via enzyme-monoclonal antibody conjugates," Anti-Cancer Drug Design, 9 (1994), pp. 409-423. |
Houba, Pieter H.J., et al., "Characterization of Novel Anthracyline Prodrugs Activated by Human .beta.-glucuronidase for Use in Antibody-Directed Enzyme Prodrug Therapy," Biochemical Pharmacology, 52 (1996), pp. 455-463. |
Leenders, Ruben G.G., et al., ".beta.-Glucuronyl Carbamate Based Pro-moieties Designed for Prodrugs in ADEPT," Tetrahedron Letters, 36 (1995), pp. 1701-1704. |
Sinhababu, Anchintya K., et al., "Review Prodrugs of anticancer agents," Advanced Drug Delivery Reviews, 19 (1996), pp. 241-273. |
Fiebig et al., Comparison of Tumor Response in Nude Mice and in the Patients, Behring Inst. Mitt., No. 74, pp. 343-352 (1984). |